European investment trends by UK investment trusts, Kepler Analysis

Europe

In this research note, Kepler explores the performance and investment landscape of European equities, emphasizing the importance of focusing on individual companies rather than macroeconomic conditions. The report highlights several leading companies, such as Novo Nordisk and ASML, and discusses how European equity markets, including those covered by Fidelity European Trust plc (LON:FEV) and JPMorgan European Discovery plc (LON:JEDT), benefit from global revenues and trends. The note also examines fund flows and geographical weightings, suggesting that despite a challenging macroeconomic outlook, European equities offer compelling opportunities driven by world-class companies in various sectors.

What this piece isn’t trying to do is cast any economic forecasts for European countries, and in truth, it’s not hard to find plenty of negatives to talk about if one wants to. At the heart of things, we are just intrigued by the fact that last year European stock markets performed well, driven by good operational performance by many of its largest companies, rather than by a valuation recovery from the lows reached in 2022, but at the same time investors continued to shun the region. And as it turns out the Europe that fund managers invest into has a brighter economic track record than the Europe we think of when we just look at the sizes of the economies that make up the whole. We’ve been asked a fair bit this year whether very strong fund flows into US equities are a signal that it’s time to jump ship, and our view is that when one is dealing with explosively growing companies, it can become complicated to answer such a question. What seems less complicated to us is that Europe has shown it has some great, world-leading companies in which investors have shown limited interest by comparison to the Magnificent Seven, and yet the economic reality for many countries is much more positive than the common narrative. This seems to us to be a convergence of things that could lead to very strong performance once investors fully grasp the situation.

Share on:
Find more news, interviews, share price & company profile here for:

JPMorgan European Discovery Trust Factsheet August 2025: European sentiment strengthens

JEDT performance over the year remains highly encouraging. The share price has climbed 28.3% and NAV 22.8% over twelve months, both comfortably ahead of the benchmark’s 14.1% rise.

Investing in Europe: Why investors should remain positive

Co-Portfolio Manager of the Fidelity European Trust PLC (LON:FEV), outlines why he believes quality businesses backed by strong balance sheets and dividend growth potential remain well placed to deliver strong relative returns over the long-term.

Fidelity European Trust rises in August, reporting 16.4% returns in 2025

Fidelity European Trust highlighted strong contributions in August 2025 from KBC Groupe, which upgraded full year guidance, and Novo Nordisk, which advanced on positive trial results and regulatory approval for Wegovy.

JPMorgan European Discovery Trust reports strong performance uplift in latest factsheet

JPMorgan European Discovery Trust reported a 5.37% share price rise in July 2025, outpacing NAV and its benchmark. Year-to-date, the share price is up 34.17%, supported by strong small-cap performance and effective stock selection.

Fidelity European Trust Factsheet – July volatility, Legrand and Bankinter gains

Continental European equities were volatile in July, with the Trust underperforming the index due to weak stock selection in financials and healthcare. Novo Nordisk and ASML detracted, while Legrand and Bankinter contributed positively. Over 12 months, the Trust’s NAV rose 1.8% and the share price 1.7%, compared with an 11.3% gain for the index.

Search

Search